Global Cord Blood Corp operates in the Health and allied services sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Global Cord Blood Corp with three other
health care providers in Asia:
Green Cross Lab Cell Corp
of KOREA (SOUTH)
sales of 85.56 billion Korean Won [US$76.66 million]
of which 72%
was Clinical Laboratory Services),
Human Health Holdings Ltd
of HONG KONG
(453.74 million Hong Kong Dollars [US$58.46 million]
of which 59%
was General practice services), and
Cordlife Group Limited
based in SINGAPORE
(50.62 million Singapore Dollars [US$38.17 million]
of which 95%
During the third
quarter of 2021, sales at Global Cord Blood Corp totalled
290.80 million Chinese Renmimbi.
This is a drop of 13.1%
from the 334.73 million Chinese Renmimbi in sales at the company during the third quarter in 2020.
This was the biggest quarterly decline in sales at Global Cord Blood Corp in the previous 36 quarters.
During the first three quarters of 2021, sales totalled 857.32 million Chinese Renmimbi, which is
than through the first three
quarters of 2020.
Global Cord Blood Corp reported sales of 1.22 billion Chinese Renmimbi (US$190.94 million)
March of 2020.
increase of 23.8%
versus 2019, when the company's sales were 986.75 million Chinese Renmimbi.
Sales at Global Cord Blood Corp have increased during each of the previous five years
(and since 2015, sales have increased a total of 92%).